Abstract
Background: Angiotensin II (Ang II) has been shown in preclinical work to increase TGF-β production through AT1 receptor signaling and to decrease TGF-β through AT2 receptor signaling. Thus, the ang II pathway through overlap with the TGF-β pathway may have a critical role in carcinogenesis as well as immune evasion and inhibiting AT1 may enhance clinical responses in combination with PD(L)1 blockade. Here we report efficacy of anti PD(L)1 based therapy in pts with advanced solid tumors concomitantly taking angiotensin receptor blockers (ARBs).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
